Figures & data
Table 1 Baseline Characteristics of the 67 Patients with Previously Immunotherapy Treated Advanced NSCLC
Figure 2 Waterfall plot for the best change in target lesion among the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration (Blue columns represent PR, yellow columns represent SD and red columns represent PD during the best overall response).
![Figure 2 Waterfall plot for the best change in target lesion among the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration (Blue columns represent PR, yellow columns represent SD and red columns represent PD during the best overall response).](/cms/asset/8c8ed67c-75e5-471e-92df-b4c467655c9c/dlct_a_12301561_f0002_c.jpg)
Figure 3 Progression-free survival of the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration.
![Figure 3 Progression-free survival of the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration.](/cms/asset/aad8b108-44c9-4e5c-80d0-b759e7ee92d2/dlct_a_12301561_f0003_c.jpg)
Figure 4 Overall survival of the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration.
![Figure 4 Overall survival of the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration.](/cms/asset/350494b6-8195-4cf8-8d0c-4ec31305d17e/dlct_a_12301561_f0004_c.jpg)
Figure 5 Comparison of overall survival in the 67 patients with advanced NSCLC who received anlotinib plus PD-1 blockades administration according to the response status of previous immunotherapy.
![Figure 5 Comparison of overall survival in the 67 patients with advanced NSCLC who received anlotinib plus PD-1 blockades administration according to the response status of previous immunotherapy.](/cms/asset/a9dfc64c-be27-4d40-9cb4-70f3838345e8/dlct_a_12301561_f0005_c.jpg)
Table 2 Safety Profile of the 67 Patients with Previously Immunotherapy Treated Advanced NSCLC Who Received Anlotinib Plus PD-1 Blockades